Steiger M J, Stocchi F, Bramante L, Ruggieri S, Quinn N P
Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, U.K.
Clin Neuropharmacol. 1992 Dec;15(6):501-4. doi: 10.1097/00002826-199212000-00007.
For many patients with Parkinson disease and levodopa-related motor fluctuations, the latency to onset of action of a single dose of a levodopa preparation may be both long and variable. In an effort to find a more rapidly acting and reliable preparation of levodopa, we therefore studied the efficacy of single doses of an oral solution of 250 mg of levodopa methyl ester (ME) with benserazide, 50 mg and of a molar equivalent dose of dispersible Madopar (DM) (50/200) in 13 patients in the fasting state after overnight drug withdrawal. The response of seven of these patients was compared to that after two Sinemet 25/100. The latency to "on" was equally fast with ME and DM, and significantly faster than after standard Sinemet. The duration of "on" was similar with all three. Because of this more rapid relief of "off" periods, both ME and DM offer a potential clinical advantage over standard preparations of levodopa.
对于许多帕金森病患者以及与左旋多巴相关的运动波动患者而言，单剂量左旋多巴制剂起效的潜伏期可能既长且存在差异。因此，为了找到一种起效更快且更可靠的左旋多巴制剂，我们研究了在隔夜停药后的空腹状态下，13例患者服用250毫克左旋多巴甲酯（ME）与50毫克苄丝肼的口服溶液单剂量以及摩尔等效剂量的可分散片剂美多芭（DM）（50/200）的疗效。将其中7例患者的反应与服用两片息宁25/100后的反应进行了比较。ME和DM达到“开”状态的潜伏期同样快，且显著快于标准息宁后的潜伏期。三种药物的“开”状态持续时间相似。由于能更快缓解“关”期，ME和DM相较于标准左旋多巴制剂均具有潜在的临床优势。
